RSS Feed Print
Avonex
Molokai16
Posted: Thursday, September 19, 2019 7:15 AM
Joined: 10/23/2018
Posts: 89


Anyone have info or experience with Avonex?
Jo C.
Posted: Thursday, September 19, 2019 8:07 AM
Joined: 12/9/2011
Posts: 10227


Use in Multiple Sclerosis?  Avonex - Interferon, beta 1a; used in MS and off label for lesser forms of MS.

I have not seen nor found it online used in dementia; that is why I ask about the condition the Avonex would be used for.

J.


Lane Simonian
Posted: Thursday, September 19, 2019 10:00 AM
Joined: 12/12/2011
Posts: 4602


Here is a link to trial information for a similar Interferon-beta drug:

https://clinicaltrials.gov/ct2/show/NCT01075763

There is both good and bad news with this approach.  First the good news:

IFN-beta suppressed the production of glutamate and superoxide by activated microglia to 70% and 75% of lipopolysaccharide stimulation, respectively, and prevented microglial-induced neuronal cell death.

Microglia induced neuronal cell death is one of the features of Alzheimer's disease.

But here is the bad news:

IFN-beta did not prevent neuronal cell death induced by the peroxynitrite donor 3-morpholinosydnonimine (SIN-1) or ionotropic glutamate receptor agonists such as N-methyl-D-aspartic acid (NMDA)...

Microglia kill neurons through the production of peroxynitrite, but peroxynitrite can also be produced independently of microglia via NMDA receptors.  Apparently there is a limit to the amount of peroxynitrite-mediated neuronal cell death INF-beta drugs can reduce.  Maybe they can do some good for some time.


Lane Simonian
Posted: Thursday, September 19, 2019 10:30 AM
Joined: 12/12/2011
Posts: 4602


Here are the results using the IFN-beta1a drug Rebif for Alzheimer's disease:

Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer’s Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.

Our study was clearly not powered to demonstrate efficacy. However, although no statistically significant difference between the IFNβ1a and the placebo groups was reported for the major outcome measure of the study, the ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognition] score, the improvement noted in the IFNβ1a treatment group was maintained during the 24-week follow-up period. Similarly, improvement in the ADAS-NonCog [non-cognitive assessments such as behavior] score was maintained. Importantly, significant improvements in the IADL and in the PSMS scores, extending to the follow-up phase, were observed in the IFNβ1a treatment group.

These results show that, although treatment with IFNβ1a did not perform better than placebo during the treatment period, a slower decline could be observed in the active drug group during the follow-up period, indicating a prolonged protective effect of IFNβ1a. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931325/

This is almost exactly what one would expect from this drug and the outcome for Avonex should be similar: good but not great.


Jo C.
Posted: Thursday, September 19, 2019 6:55 PM
Joined: 12/9/2011
Posts: 10227


 https://multiplesclerosisnewstoday.com/avonex-multiple-sclerosis/